Sumit Rawal Selected Research

XMT 1001

5/2012

Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sumit Rawal Research Topics

Disease

5	Neoplasms (Cancer) 11/2014 - 05/2012
2	Aflatoxin Poisoning 03/2015 - 10/2014
2	Carcinoma (Carcinomatosis) 07/2013 - 05/2012
1	Coinfection 03/2015
1	Necrosis 10/2014
1	Breast Neoplasms (Breast Cancer) 01/2013

Drug/Important Bio-Agent (IBA)

2	Pharmaceutical PreparationsIBA 11/2014 - 05/2012
1	lymphotactinIBA 03/2015
1	VaccinesIBA 03/2015
1	Granzymes (Granzyme)IBA 03/2015
1	PerforinIBA 03/2015
1	Aflatoxin B1 (Aflatoxin B)IBA 10/2014
1	LipidsIBA 01/2014
1	Docetaxel (Taxotere)FDA Link 07/2013
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2013
1	liposomal doxorubicin (Doxil)FDA Link 01/2013
1	Liposomes (Liposome)IBA 01/2013
1	1-dodecylpyridoxal (PLD)IBA 01/2013
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 05/2012
1	Topoisomerase I InhibitorsIBA 05/2012
1	Irinotecan (Camptosar)FDA LinkGeneric 05/2012
1	XMT 1001IBA 05/2012
1	CamptothecinIBA 05/2012

Therapy/Procedure

1	Chemoprevention 10/2014